Elelyso
Elelyso Uses, Dosage, Side Effects, Food Interaction and all others data.
Elelyso is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Patient's with Type 1 Gaucher disease have a long-term deficiency in the enzyme, glucocerebrosidase. Elelyso is a modified form of glucocerebrosidase and is provided to counter this enzyme deficiency, resulting in smaller liver and spleen size, and improved thrombocytopenia and anemia.
Trade Name | Elelyso |
Generic | Taliglucerase alfa |
Taliglucerase alfa Other Names | Glucosylcerebrosidase, prGC-D, prGCD, Taliglucerase alfa |
Weight | 200units, |
Type | Injection, Powder, Lyophilized, For Solution, Intravenous Powder For Injection |
Formula | C2580H3918N680O727S17 |
Weight | 56637.9397 Da |
Protein binding | Plasma protein binding was not quantified. |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | Australia, Canada, United States, |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Elelyso is a hydrolytic lysosomal glucocerebroside specific enzyme, used for long term enzyme replacement therapy in patients with Type 1 Gaucher disease.
For the treatment of adult Type 1 Gaucher disease.
Elelyso is also used to associated treatment for these conditions: Gaucher Disease, Type 1, Type 3 Gaucher disease
How Elelyso works
Elelyso is different from human glucocerebrosidase by two amino acids at the N terminal and up to 7 amino acids at the C terminal. This recombinant enzyme allows the hydrolysis reaction of glucocerebroside to glucose and ceramide that naturally occurs in healthy individuals.
Toxicity
The most common toxic reaction seen was infusion reactions such as urticaria, arthralgia, headache, and chest pain due to IV administration.
Food Interaction
- Take with or without food.
Volume of Distribution
The steady state volume of distribution is between 7.30 to 11.7 L.
Elimination Route
Elelyso is administered IV so absorption is 100%.
Half Life
The half life is between 18.9 to 28.7 min.
Clearance
The systemic clearance was approximately 30 L/hr and 20 L/hr for 30 and 60 units/kg, respectively.
Elimination Route
Route of elimination was not determined.
Innovators Monograph
You find simplified version here Elelyso